Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Taipei Exchange - Delayed Quote TWD

Pharmosa Biopharm Inc. (6875.TWO)

51.60
+4.30
+(9.09%)
At close: 1:30:39 PM GMT+8

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in TWD.
NameTitlePayExercisedYear Born
Dr. Pei Kan Ph.D. President, GM & Director 4.55M -- --
Mr. Hui-An Pao Vice President of Operations -- -- --
Ms. Ru-Yun Lin M.B.A. Vice President of Administration -- -- 1966

Pharmosa Biopharm Inc.

No. 508, Sec. 7, Zhongxiao E. Rd.
11F / 11F-1. Nangang District
Taipei City
Taiwan
886 2 2782 7561 https://www.pharmosa.com.tw
Sector: 
Healthcare
Industry: 
Biotechnology

Description

Pharmosa Biopharm Inc., a biotechnology company, focuses on developing drugs in Taiwan. It develops L606, an inhalation/device combination for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; and L608, an inhalation/device combination for the treatment of pulmonary vascular disease. The company was formerly known as Pharmosa Limited and changed its name to Pharmosa Biopharm Inc. in October 2016. Pharmosa Biopharm Inc. was founded in 2000 and is headquartered in Taipei City, Taiwan.

Corporate Governance

Pharmosa Biopharm Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

Recent Events

Related Tickers